WO2019199896A1 - Anticorps agonistes contre le cd137 humain dans le cancer exprimant le cmh i - Google Patents

Anticorps agonistes contre le cd137 humain dans le cancer exprimant le cmh i Download PDF

Info

Publication number
WO2019199896A1
WO2019199896A1 PCT/US2019/026675 US2019026675W WO2019199896A1 WO 2019199896 A1 WO2019199896 A1 WO 2019199896A1 US 2019026675 W US2019026675 W US 2019026675W WO 2019199896 A1 WO2019199896 A1 WO 2019199896A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
nos
monoclonal antibody
antigen binding
Prior art date
Application number
PCT/US2019/026675
Other languages
English (en)
Other versions
WO2019199896A9 (fr
Inventor
Ugur ESKIOCAK
Original Assignee
Compass Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Therapeutics Llc filed Critical Compass Therapeutics Llc
Publication of WO2019199896A1 publication Critical patent/WO2019199896A1/fr
Publication of WO2019199896A9 publication Critical patent/WO2019199896A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La présente invention concerne des procédés de traitement ou d'amélioration d'un ou plusieurs symptômes du cancer, à l'aide d'anticorps agonistes, et de fragments de liaison à l'Antigène de ceux-ci, qui se lient à CD137, les cellules cancéreuses exprimant le complexe majeur d'histocompatibilité I (CMH I).
PCT/US2019/026675 2018-04-09 2019-04-09 Anticorps agonistes contre le cd137 humain dans le cancer exprimant le cmh i WO2019199896A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862655066P 2018-04-09 2018-04-09
US62/655,066 2018-04-09
US201862755644P 2018-11-05 2018-11-05
US62/755,644 2018-11-05

Publications (2)

Publication Number Publication Date
WO2019199896A1 true WO2019199896A1 (fr) 2019-10-17
WO2019199896A9 WO2019199896A9 (fr) 2020-03-05

Family

ID=66440133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/026675 WO2019199896A1 (fr) 2018-04-09 2019-04-09 Anticorps agonistes contre le cd137 humain dans le cancer exprimant le cmh i

Country Status (1)

Country Link
WO (1) WO2019199896A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022242679A1 (fr) * 2021-05-21 2022-11-24 Beigene, Ltd. Anticorps anti-cd137 et procédés d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069703A1 (fr) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Schémas posologiques immunothérapeutiques et combinaisons de ceux-ci

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069703A1 (fr) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Schémas posologiques immunothérapeutiques et combinaisons de ceux-ci

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. YONEZAWA ET AL: "Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy", CLINICAL CANCER RESEARCH, vol. 21, no. 14, 23 April 2015 (2015-04-23), US, pages 3113 - 3120, XP055413752, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-15-0263 *
ANTHONY W. TOLCHER ET AL: "Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH, vol. 23, no. 18, 15 September 2017 (2017-09-15), US, pages 5349 - 5357, XP055551241, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-1243 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022242679A1 (fr) * 2021-05-21 2022-11-24 Beigene, Ltd. Anticorps anti-cd137 et procédés d'utilisation

Also Published As

Publication number Publication date
WO2019199896A9 (fr) 2020-03-05

Similar Documents

Publication Publication Date Title
US11752207B2 (en) Agonist antibodies that bind human CD137 and uses thereof
AU2019235842B2 (en) Antibodies that bind CD39 and uses thereof
WO2021142002A1 (fr) Anticorps anti-ccr8 et leurs utilisations
US20240002525A1 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019199896A9 (fr) Anticorps agonistes contre le cd137 humain dans le cancer exprimant le cmh i
US20220111047A1 (en) Formulations of antibodies that bind human cd137 and uses thereof
US20210388089A1 (en) Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (fr) Anticorps qui se lient à cd277 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19722746

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19722746

Country of ref document: EP

Kind code of ref document: A1